Cargando…
Inhaled mometasone furoate for the management of refractory oral corticosteroid-dependent asthma: a case report
We report a case study of a 55-year-old white male with severe persistent refractory corticosteroid-dependent asthma receiving inhaled combination therapy with fluticasone propionate 500 μg and salmeterol 50 μg twice-daily in addition to 6-week cycles of oral corticosteroid treatment for the previou...
Autor principal: | Nsouli, Talal M |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2827114/ https://www.ncbi.nlm.nih.gov/pubmed/20181197 http://dx.doi.org/10.4076/1757-1626-2-7770 |
Ejemplares similares
-
Mometasone furoate in the management of asthma: a review
por: Tan, Ricardo A, et al.
Publicado: (2008) -
Comparison of the systemic bioavailability of mometasone furoate after oral inhalation from a mometasone furoate/formoterol fumarate metered-dose inhaler versus a mometasone furoate dry-powder inhaler in patients with chronic obstructive pulmonary disease
por: Kosoglou, Teddy, et al.
Publicado: (2013) -
Comparative safety and efficacy of topical mometasone furoate with other topical corticosteroids
por: Spada, Fabrizio, et al.
Publicado: (2018) -
Zein nanoparticles as oral carrier for mometasone furoate delivery
por: Zimath, Priscila, et al.
Publicado: (2023) -
Long-term safety of Mometasone Furoate administered via a dry powder inhaler in children: Results of an open-label study comparing Mometasone Furoate with Beclomethasone Dipropionate in children with persistent asthma
por: Noonan, Michael, et al.
Publicado: (2009)